FBLG

Fibrobiologics, Inc. (FBLG) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2026. Fibrobiologics, Inc. is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases, including wound healing (CYWC628), psoriasis (CYPS317), multiple sclerosis (CYMS101), and degenerative disc disease (CybroCell). The company is classified as a smaller reporting company and an emerging growth company. On March 30, 2026, the company effected a 1-for-20 reverse stock split.

Key Financial Metrics

Note: All financial figures are in thousands unless otherwise noted. The filing does not provide specific gross margin data as the company has no revenue.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by $0.5 million to $5.1 million. Research and Development (R&D) expenses rose by $1.2 million (to $3.0 million) primarily due to increased Contract Research Organization (CRO) costs of $1.8 million to prepare for clinical trials. General and Administrative (G&A) expenses decreased by $0.6 million (to $2.1 million) due to lower personnel and professional fees.
• Liquidity: Cash and cash equivalents decreased by $3.4 million, driven by a net cash burn of $4.4 million from operations, partially offset by $0.95 million in financing activities (SEPA sales and loan proceeds).
• Other Income/Expense: The company recorded a $0.05 million gain from the change in fair value of the SEPA put option liability, compared to a loss in the prior year. Interest income decreased to $0.02 million.
• Capital Structure: The company issued 133,108 shares under its Standby Equity Purchase Agreement (SEPA) for approximately $0.7 million in proceeds during the quarter.

Outlook, Risks, and Management Commentary

• Going Concern: Management has concluded there is substantial doubt about the company's ability to continue as a going concern for one year from the issuance date. The company has an accumulated deficit of $59.2 million and requires additional capital to fund operations.
• Clinical Pipeline:
  • CYWC628 (Wound Healing): Manufacturing of the master cell bank is complete. The Phase 1/2 trial in Australia for diabetic foot ulcers is expected to begin patient screening in Q2 2026. Timelines were extended due to manufacturing process issues and low yields in initial batches.
  • CYPS317 (Psoriasis): An IND application was filed with the FDA in December 2025; the company is updating the submission based on feedback.
  • CYMS101 (Multiple Sclerosis): A Phase 1 study in Mexico was completed with no adverse events. An IND for a U.S. Phase 1/2 trial is planned for 2026.
• Internal Controls: Management identified a material weakness in internal controls over financial reporting due to a lack of segregation of duties. A remediation plan involving hiring additional accounting staff is underway.
• Nasdaq Compliance: The company recently resolved delisting notices regarding bid price and market value standards. It remains subject to a Mandatory Panel Monitor for one year.
• Subsequent Event: On April 2, 2026, the company completed a registered offering raising approximately $2.5 million in net proceeds.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $1.5 million cash balance against the $4.4 million quarterly burn rate and the timeline for the subsequent $2.5 million financing to close.
• Manufacturing Risks: Assess the impact of low yields and process issues with the CDMO on the timeline and cost of the CYWC628 Australian trial.
• Going Concern Status: Review the specific terms and likelihood of success for future equity or debt financings required to alleviate the substantial doubt disclosure.
• Internal Controls: Monitor the progress of the remediation plan for the material weakness in financial reporting segregation of duties.
• Nasdaq Listing: Confirm continued compliance with Nasdaq Capital Market bid price and equity standards during the one-year monitoring period.